SCIENCE & HEALTH
For decades, the treatment for one of the strangest cancers in medicine has looked less like modern oncology than like something out of a Victorian sickroom: you take the patient's blood out. Then you do it again. And again. Sometimes every two weeks. Sometimes for the rest of their life.
It is called therapeutic phlebotomy, and it is the frontline treatment for polycythemia vera — a chronic blood cancer in which the bone marrow simply will not stop manufacturing red blood cells. The blood thickens. It slows. It clots. And then, without warning, it can throw a stroke, a deep vein thrombosis, or a pulmonary embolism at a patient who felt merely tired the day before.
On Friday, August 28, that century-old ritual finally got a serious rival. The U.S. Food and Drug Administration approved Mimrylo — generic name rusfertide — the first drug of its kind ever cleared for polycythemia vera, and the first approved medicine anywhere that works by imitating hepcidin, the body's own master hormone for controlling iron.
It is a once-weekly injection that patients give themselves at home. In the pivotal trial, roughly three out of four patients on it did not need a single blood draw over a critical 12-week window. In the placebo group, only one in three could say the same.
The Disease That Makes Too Much Life
Polycythemia vera — PV to the people who live with it — is what happens when a single mutated stem cell in the bone marrow decides the body needs more red blood cells and refuses to be argued with. Most cases trace back to a mutation in a gene called JAK2, which jams the marrow's accelerator pedal permanently to the floor.
The result is erythrocytosis: an overproduction of red blood cells that raises the hematocrit — the percentage of your blood volume made up of red cells — to dangerous levels. Normal is somewhere in the low forties. In PV, it can climb well past 50. And thick blood is slow blood.
About 90,000 people in the United States are living with PV, according to figures cited by Takeda, the Japanese pharmaceutical giant that will market Mimrylo. It is not a disease that announces itself dramatically. It creeps. Patients describe crushing fatigue that no amount of sleep touches. There is pruritus — a maddening, full-body itch that classically strikes after a hot shower and has driven patients to cold baths at three in the morning. There are night sweats. There is a brain fog that makes holding a conversation feel like wading through mud.
And there is the constant, low-grade dread. Because the real threat in PV is not the itching. It is the clot.
Patients with PV whose hematocrit stays uncontrolled face roughly four times the risk of cardiovascular death or a major cardiovascular event, according to landmark data published in the New England Journal of Medicine.
Which is why the treatment goal in PV has been the same for years and is brutally simple: get the hematocrit below 45 percent, and keep it there. Forever.
The Needle Treadmill
Getting there has traditionally meant one of two things, and usually both.
The first is phlebotomy — the deliberate removal of roughly a pint of blood, over and over, to physically reduce the red cell count. It is effective. It is also, for many patients, a life sentence of appointments: time off work, veins that scar over from repeated sticks, the peculiar exhaustion that follows a blood draw, and the iron deficiency that inevitably follows years of it.
The second is cytoreductive therapy: drugs such as hydroxyurea, interferon, or ruxolitinib that suppress the marrow's output more broadly. These help many patients. They do not help enough of them.
Here is the statistic that explains why the FDA approval matters: an estimated 78 percent of PV patients still experience uncontrolled hematocrit on current standard of care — including phlebotomy and cytoreductive drugs. Nearly four out of five. The existing playbook, in other words, is failing most of the people playing by it.
"For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Dr. Andrew T. Kuykendall, the lead investigator on the trial that won the approval and an associate member in the Department of Hematology at Moffitt Cancer Center in Tampa. "Current treatments, such as phlebotomy, leave a significant gap for too many patients and can pose challenges to daily life and routines."
How You Starve a Blood Factory
The science behind Mimrylo is elegant enough that it is a little surprising nobody got it across the finish line sooner.
Red blood cells are built out of iron. Without iron, the marrow physically cannot assemble hemoglobin, and production stalls. The body already has a hormone that regulates how much iron is available for this: hepcidin, produced by the liver, which acts as a kind of gatekeeper controlling how much iron gets absorbed from food and released from the body's storage depots.
Mimrylo is a hepcidin mimetic. It is a synthetic peptide that imitates that natural hormone, locking iron away in storage where the bone marrow cannot reach it. Starved of raw material, the runaway red-cell assembly line slows down — not because the drug attacks the cancerous stem cell, but because it quietly cuts off the supply chain.
It is a strikingly indirect way to treat a cancer. It also means the drug does not carry the broad marrow-suppressing baggage of traditional cytoreductive therapy.
"Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden," said Dr. Tanya Wroblewski, Director of the Division of Nonmalignant Hematology within the FDA's Center for Drug Evaluation and Research, in the agency's announcement.
The Trial: 293 Patients, One Very Clear Number
The approval rests on VERIFY, a global, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 293 adults with polycythemia vera. Crucially, these were not easy cases. Every participant was phlebotomy-dependent despite already being on standard-of-care treatment — the exact population the current playbook has been failing.
Patients were randomly assigned one-to-one to either Mimrylo or placebo, both layered on top of whatever treatment they were already receiving. Mimrylo was started at 19 milligrams, injected under the skin once weekly, and adjusted to hold hematocrit below 45 percent.
The primary endpoint was deliberately concrete: what proportion of patients avoided meeting the criteria for a blood draw between weeks 20 and 32 of the study?
The answer: 76.9 percent of patients on Mimrylo required no phlebotomy during that window, versus 32.9 percent on placebo.
The secondary numbers reinforced it. Across the first 32 weeks, patients on Mimrylo averaged 0.5 phlebotomies each. Patients on placebo averaged 1.8. At the 52-week mark, the median time to a first blood draw had not even been reached in the Mimrylo group — meaning more than half of them still had not needed one. In the placebo group, the median was 16 weeks.
Mean hematocrit sat below 43 percent in patients who stayed on Mimrylo, and in those who crossed over from placebo.
The drug also hit all four key secondary endpoints, including a measured improvement in fatigue on the PROMIS Fatigue Short Form 8a — which matters more than it might sound, because fatigue is the symptom PV patients consistently rank as the most life-limiting.
The Fine Print: What It Costs and What It Does
No drug arrives without a bill or a warning label, and Mimrylo has both.
The most common side effects were injection site reactions — reported in roughly 56 percent of treated patients, versus about 33 percent on placebo — including redness, itching, pain and swelling. Some were severe enough to be graded as serious. The FDA's guidance is practical: ice, topical steroid creams, antihistamines, or painkillers as needed.
Anemia was the second most common reaction, at about 16 percent versus 4 percent on placebo — an unsurprising consequence of a drug whose entire mechanism is restricting iron.
More significant is a warning about thrombocytosis: Mimrylo can push platelet counts up in PV patients. Doctors are told to monitor complete blood counts every two to four weeks after starting the drug and during any dose changes. Platelet counts generally plateaued by week eight in the trial, but elevations may require adding or adjusting cytoreductive therapy — or reducing or stopping Mimrylo altogether.
There is also a hard stop for pregnancy. Based on animal reproduction studies, Mimrylo may cause fetal harm. Pregnancy testing is recommended before starting, effective contraception is advised during treatment and for at least 30 days after the final dose, and patients are told to stop the drug if they become pregnant. Breastfeeding is not advised during treatment or for 30 days afterward, because of the risk of impaired iron absorption in the infant.
Then there is the price. Mimrylo carries a list price of $4,200 per vial. At one vial per weekly dose, that works out to roughly $218,400 a year before insurance, rebates or patient assistance.
It is a number that has not gone unnoticed on Wall Street. Analysts at Jefferies have projected peak annual sales for Mimrylo of around $2 billion. The approval also triggered a $275 million milestone payment to Protagonist Therapeutics, the biotech that discovered the drug and carried it through Phase 3 before handing global commercialization rights to Takeda.
Expert Perspective: A Shift, Not a Cure
The people closest to this disease are being careful with their language — and that care is worth noting.
Kuykendall, the lead investigator, framed the result in terms of confidence rather than triumph: "The strength and consistency of the VERIFY data give me real confidence in Mimrylo's potential to advance how we treat PV in everyday practice and to maintain hematocrit control."
The patient advocacy community was similarly measured. "People living with PV often experience complex and invisible symptoms, from extreme fatigue to the emotional strain of living with a chronic blood cancer," said Kapila Viges, chief executive of the MPN Research Foundation. "At the same time, we know that every patient's experience with PV is different, underscoring the need to continue to listen closely to the community to understand what matters most."
Her framing — "important progress" and "a new treatment option" rather than a breakthrough cure — is the honest one. Mimrylo does not eliminate the JAK2-mutated stem cell driving the disease. It does not, on the evidence so far, reverse polycythemia vera or stop it from progressing over decades into myelofibrosis or acute leukemia, the feared endpoints for a minority of patients.
What it does is control the single number most tightly linked to whether a PV patient has a stroke this year. And it does so while lifting the phlebotomy burden that has defined life with this disease since before antibiotics existed.
It is also worth being clear about what the trial did not measure. VERIFY was designed around phlebotomy avoidance and hematocrit control — not around whether patients on Mimrylo actually suffer fewer strokes and clots over the long run. The link between controlled hematocrit and reduced thrombotic risk is well established from prior research, but proving that Mimrylo specifically translates into fewer catastrophic events will take years more data. The open-label extension of VERIFY runs to 156 weeks and beyond, and Takeda says it will present further findings at upcoming medical conferences.
What This Means for You
If you or someone in your family has polycythemia vera, here is the practical translation.
1. This is aimed squarely at people phlebotomy is failing.
The VERIFY population was specifically patients who still needed frequent blood draws despite being on standard treatment. If your hematocrit is well controlled on hydroxyurea or interferon and you rarely need phlebotomy, this drug may not change your regimen. If you are on the needle treadmill every few weeks, it is a conversation to have with your hematologist now.
2. It is a self-injection, not an infusion.
Mimrylo is given subcutaneously once a week and was self-administered by patients in the trial. For anyone whose life is structured around clinic appointments, that is a meaningful change in day-to-day logistics.
3. Expect blood tests, at least at first.
Because of the platelet warning, complete blood counts every two to four weeks are recommended when starting and during dose adjustments. The drug reduces blood draws for treatment; it does not eliminate blood draws for monitoring.
4. Ask about cost before you ask about anything else.
At a list price north of $200,000 a year, coverage will be the deciding factor for most patients. Ask your care team about Takeda's patient support programs, prior authorization requirements, and what your specific plan's specialty pharmacy tier looks like.
5. Know the warning signs regardless.
Whatever treatment you are on, the reason all of this matters is clot risk. Sudden severe headache, one-sided weakness or facial droop, slurred speech, unexplained swelling and pain in one leg, sudden shortness of breath or chest pain — these are emergencies in anyone, and they are red alerts in someone with PV.
And for readers without PV: the symptom that most often sends people to a doctor and eventually to this diagnosis is not dramatic. It is persistent, unexplained itching after a hot shower, combined with fatigue and a routine blood test showing a high red cell count. It is worth taking seriously.
The Bottom Line
Medicine moves in strange rhythms. Some diseases get a decade of headline-grabbing innovation. Others get nothing for a century, and then a single Friday afternoon press release changes the arithmetic.
Polycythemia vera has been treated by draining blood since the era when doctors wore frock coats. That treatment was not wrong — it works, and it has kept an enormous number of people alive. But it was never anything more than a way to manage a symptom by physically removing it, over and over, until the patient died of something else.
Mimrylo is the first approved drug to go after the machinery instead: to reach into the body's iron economy and quietly close the tap that feeds the runaway factory. Whether it eventually proves to reduce strokes and clots at the population level is a question only long-term data can answer, and the price tag will determine how many patients ever get the chance to find out.
But for the roughly 78 percent of PV patients whose hematocrit is not adequately controlled today, and for the thousands who have organized their calendars around blood draws for years, a first-in-class option is not a small thing. Takeda says it is now working with regulators outside the United States to bring Mimrylo to patients worldwide. The needle is not gone. But for the first time, it might not be the whole plan.
